Article

USE OF BLOOD PRODUCTS IN ONCOLOGICAL PATIENTS TREATED WITH RADIO AND CHEMOTHERAPY

Acta Medica Medianae 01/2008;

ABSTRACT Retrospectively, we analyzed the use of blood products in Oncological Clinic of Clinical Center Nis in the period November 1st 2007-November 1st 2008, and also the influence of the treatment on degree of anemia and thrombocytopenia and use of blood products. None of the patients received the whole blood. In this period, 324 patients received the transfusion of blood components, 302 patients received 983 units of red cells (red blood cell concentrate, resuspended, washed, filtered), 17 patients received 5050 ml of platelets (single-donor concentrate or pooled platelet concentrate) and 5 patients received 2200 ml of fresh frozen plasma. An average use of red cell transfusion is 3,26 units, platelet concentrate 5,54, fresh frozen plasma 2 units per oncological patient who receives transfusion. The use of red cell units and platelet concentrate transfusion was adequate (91,85% of patients received transfusion of red cells when Hgb<70g/l, 89,2% of patients received platelet concentrate transfusion when platelet count was less than 20 x109/l). During radio and chemotherapy we noticed a decrease of hematological parameter values, whereas the experimental group patients were dependent on blood product transfusion. Statistically, a significant decrease of hemoglobin level and platelet count was observed in the patients treated only with radiotherapy, who are the greatest consumers of blood products.

0 Bookmarks
 · 
142 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Febrile non-hemolytic transfusion reactions (FNHTRs) are a common complication of platelet concentrate (PC) and RBC transfusions, usually ascribed to cytokines released by WBCs and perhaps the platelets themselves during storage. Prestorage WBC reduction should abrogate the accumulation of these cytokines reducing the number of FNHTRs. A retrospective analysis of FNHTR to PCs and RBCs before universal WBC reduction (PrUR) (July 1997-January 1998 for PCs, July 1997-July 1999 for RBCs) and after its introduction (PoUR) (February 1998-August 2001 for PC, August 1999-August 2001 for RBCs) was undertaken. All transfusion reactions were stratified based on component and date of reaction. Other adverse transfusion reactions were grouped into three periods: July 1997-January 1998, February 1998-July 1999, and August 1999-August 2001. A chi-square test was performed to determine the significance of the differences between groups. In the PRUR group, there were: 231 FNHTRs in 70,396 RBC units transfused (0.33%) and 29 FNHTRs in 6502 PC units transfused (0.45% percent). In the PoUR group, there were 136 FNHTRs in 72,949 RBC units transfused (0.19%, p < 0.001) and 56 FNHTRs in 50,555 PC units transfused (0.11%, p < 0.001). Of the other adverse events, only TRALI reactions were significantly reduced. Prestorage WBC reduction significantly reduced the rate of FNHTRs to PCs and RBCs.
    Transfusion 02/2004; 44(1):10-5. · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Providing care to actively dying patients presents unique challenges for the clinician. Patients in their final days require careful symptom management. Families need support and coaching as death approaches. Care does not end with the death of the patient but continues through death pronouncement, family notification of the death, discussion of autopsy, and immediate bereavement support. Skills in these and related areas are discussed in the context of one man's death, as illuminated by comments made after death by his daughter and his physician. This case also highlights the often differing perspectives of families and clinicians as they work to deal with a patient's death. A goal of mastering the palliative skills necessary to competently care for an actively dying patient is to enable a patient to die peacefully and relatively free of discomfort. Achieving such competency should also help to relieve clinician stress attendant to caring for dying patients.
    JAMA The Journal of the American Medical Association 06/2005; 293(18):2265-71. · 29.98 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Blood product transfusions can be life saving and must be considered in the supportive care of children of any age with underlying oncological or haematological problems, as well as after major surgery or after serious trauma. Paediatric transfusions are particularly challenging because life-long effects of transfusion complications are more durable and serious in children than in adults, in whom the median age at transfusion is >70 years (Tynell E, Norda R, Shanwell A, Björkman A. Long-term survival in transfusion recipients in Sweden, 1993. Transfusion 2001, 41, 251-255). While the general indications for transfusions in paediatric patients are similar to adults, the threshold, volumes and infusion rates for transfusions vary with age. In this Update, we discuss current blood products, then suggest transfusion "triggers" in major surgery and haematological and oncologic practice. Finally, future developments and new possibilities are considered.
    European Journal of Cancer 12/2001; 37(18):2421-5; discussion 2425-7. · 5.06 Impact Factor

Full-text (2 Sources)

View
17 Downloads
Available from
May 16, 2014